Immune Regulation News Volume 12.42 | Nov 6 2020

    0
    113








    IRN 12.41 | Nov 6 2020


    Immune Regulation News by STEMCELL Technologies
    Vol. 12.42 – 6 November, 2020
    TOP STORY

    A
    General Strategy towards Personalized Nanovaccines Based on Fluoropolymers for Post-Surgical Cancer Immunotherapy

    Scientists demonstrated a general strategy to fabricate personalized nanovaccines based on a cationic fluoropolymer for post-surgical cancer immunotherapy.
    [Nature Nanotechnology]

    Full Article

    New human primary cell products—frozen leukopaks, regulatory T cells, and more. Click to view products.
    PUBLICATIONSRanked by the impact factor of the journal

    Trained
    Immunity-Promoting Nanobiologic Therapy Suppresses Tumor Growth and Potentiates Checkpoint Inhibition

    Investigators developed a bone marrow-avid nanobiologic platform designed specifically to induce trained immunity. They established the potent anti-tumor capabilities of our lead candidate MTP 10-HDL in a B16F10 mouse melanoma model.
    [Cell]

    Abstract

    Antibody
    Affinity Shapes the Choice between Memory and Germinal Center B Cell Fates

    Researchers combined lineage tracing with antibody cloning from single B cells to examine the role of affinity in B cell selection into germinal centers and the memory B cell compartment in mice immunized with an HIV-1 antigen.
    [Cell]

    AbstractGraphical Abstract

    Netrin
    G1 Promotes Pancreatic Tumorigenesis through Cancer Associated Fibroblast Driven Nutritional Support and Immunosuppression

    Scientists found that Netrin G1 (NetG1)+ cancer-associated fibroblasts (CAFs) support pancreatic ductal adenocarcinoma survival, through a NetG1 mediated effect on glutamate/glutamine metabolism. NetG1+ CAFs were intrinsically immunosuppressive and inhibited NK cell mediated killing of tumor cells.
    [Cancer Discovery]

    Abstract

    Central Memory CD8+ T Cells Derive from Stem-Like Tcf7
    hi Effector Cells in the Absence of Cytotoxic Differentiation

    Investigators uncovered rare effector-phase CD8+ T cells expressing high amounts of the transcription factor Tcf7 that showed no evidence of prior cytolytic differentiation.
    [Immunity]

    AbstractGraphical Abstract

    C/EBPα/miR-7 Controls CD4+
    T Cell Activation and Function and Orchestrates Experimental Autoimmune Hepatitis in Mice

    The authors showed that miR‐7 deficiency led to exacerbated pathology in ConA‐induced murine acute autoimmune liver injury model, accompanied with hyperactivation state of CD4+ T cells.
    [Hepatology]

    Abstract

    Neutrophil-Induced Ferroptosis Promotes Tumor Necrosis in Glioblastoma Progression

    Scientists showed that necrosis in glioblastoma (GBM) involves neutrophil-triggered ferroptosis. In a hyperactivated transcriptional coactivator with PDZ-binding motif-driven GBM mouse model, neutrophils coincide with necrosis temporally and spatially.
    [Nature Communications]

    Full Article

    BECN2
    (Beclin 2)-Mediated Non-Canonical Autophagy in Innate Immune Signaling and Tumor Development

    Investigators showed that beclin 2 functioned as a negative regulator in innate immune signaling and tumor development through non-canonical autophagy.
    [Autophagy]

    Abstract

    The
    T Cell CD6 Receptor Operates a Multitask Signalosome with Opposite Functions in T Cell Activation

    Researchers describe a CRISPR/Cas9–based platform that used primary mouse T cells and permitted establishment of the composition of their LAT, CD5, and CD6 signalosomes in only four months.
    [Journal of Experimental Medicine]

    Full Article

    Persistent STAT5 Activation Reprograms the Epigenetic Landscape in CD4+
    T Cells to Drive Polyfunctionality and Antitumor Immunity

    Scientist report that persistent activation of signal transducer and activator of transcription 5 in tumor-specific CD4+ T cells drove the development of polyfunctional T cells.
    [Science Immunology]

    Abstract

    Request a copy of the COVID-19 wallchart.
    REVIEWS

    The Future of Microfluidics in Immune Checkpoint Blockade

    Scientists look into the advancements in microfluidic technologies applied to research on immune checkpoint blockade treatment and its potential shift from proof-of-principle stage to clinical application.
    [Cancer Gene Therapy]

    Abstract

    INDUSTRY AND POLICY NEWS

    FDA
    Grants Priority Review and EMA Accepts Regulatory Submission for Pfizer’s Abrocitinib, an Oral Once-Daily JAK1 Inhibitor, for Patients 12 and Up with Moderate to Severe Atopic Dermatitis

    Pfizer Inc. announced that the FDA accepted for filing and granted Priority Review designation to the company’s New Drug Application for abrocitini, an investigational oral once-daily Janus kinase 1 inhibitor, for the treatment of moderate to severe atopic dermatitis in patients 12 and older.
    [Pfizer Inc. (BusinessWire, Inc.)]

    Press Release

    Apellis
    and Sobi Enter Collaboration for Global Co-Development and Ex-US Commercialization of Systemic Pegcetacoplan in Rare Diseases with Urgent Need for New Treatments

    Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB announced a strategic collaboration to accelerate the advancement of systemic pegcetacoplan, a targeted C3 therapy, for the treatment of multiple rare diseases with high unmet need that impact more than 275,000 patients globally.
    [Apellis Pharmaceuticals, Inc.]

    Press Release

    FEATURED EVENT

    Keystone
    Symposia: Hepatobiliary Cancers: Pathobiology and Translational Advances

    March 22 – March 24, 2021
    Virtual


    > See All Events

    JOB OPPORTUNITIES

    Senior
    Scientific Researcher – Immunology Discovery

    Genentech, Inc. – South San Francisco, California, United States

    Tier 2 Canada Research Chair – Immunology and Inflammation

    Queen’s University – Kingston, Ontario, Canada

    Postdoctoral Fellow – Cancer Immunology and Immunotherapy

    H. Lee Moffitt Cancer Center & Research Institute – Tampa, Florida, United States

    Research
    Positions – Cancer and Immunotherapy

    Terasaki Research Institute – Los Angeles, California, United States


    Assistant/Associate Professor – Immunology

    Dana-Farber Cancer Institute – Boston, Massachusetts, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Science News Immune Regulation News
    Archives Contact Us
    Immune Regulation News Twitter